Biotron partners with medical data company Diagnose.me
Analytics platform Biotron.io is partnering with medical data company Diagnose.me to combine their expertise and improve patient care worldwide. This partnership will capitalise on Biotron’s strength in data collection and analytics, and couple it with Diagnose.me’s experience in health diagnostics and research.
Biotron has chosen Diagnose.me to be their exclusive partner within the health vertical of their business. This partnership supports their mutual ambition of using data analytics to drive innovation within the healthcare industry.
“Biotron’s mission is to solve real-life problems using high-quality data and the expertise and experience that Diagnose.me has perfectly fits this goal,” commented Peter Dendis – co-founder of Biotron.io.
Thanks to new technologies and companies like Biotron, patients (the data owners) will finally benefit from the use of their medical and health information. They will have complete control over the data and how it is used and be reimbursed each time their personal information assists research and development in the medical industry.
Current state of health care data
Health records around the world are currently stored by a multitude of medical institutions and data companies, and while this information is sometimes shared, it is limited and problematic. Issues regarding privacy and accessibility make combining and analysing data from multiple sources difficult. As a result, vital information that could contribute to health research greatly lies dormant.
Privacy for patients is paramount within the healthcare industry. Though necessary, privacy implications severely limit the access medical professionals and researchers have to personal records. Accessing information requires express consent, which can be difficult to get, especially in the vast quantities needed for meaningful research.
How Biotron and blockchain offer a single solution
Biotron’s analytics platform solves the problems surrounding access to medical information. It gives physicians and researchers a resource of health data that comes directly from the people that produce it. Biotron users contribute and upload first-hand information that is timely, accurate and comprehensive. This information is then prepared for sale to customers in the healthcare industry. The global nature of the user base delivers information from across a diverse set of socio-economic and geographical backgrounds.
Peter Dendis
Privacy implications, usually associated with the use of medical records, are solved thanks to the opt-in nature of the Biotron platform. Users who produce the data, choose to share it via an app or dashboard, in return for payment. This consent can be revoked at any time, and is fully GDPR compliant. All information is pseudonymised when necessary so it cannot be attributed to an individual.
Blockchain technology is used to ensure that the people producing and offering the data are all paid for contributing their health information. It facilitates the transactions between the customers and the many data contributors. Biotron’s solution uses smart contracts to connect customers with data producers and to ensure sure that only authorised access is ever granted to health information.
Plan for 2018
In the first phase of the relationship, Biotron will create an infrastructure for a shared environment and make sure that all records are stored securely and that the legal framework is in place. Next, both partners will start on-boarding users through both Biotron’s and Diagnose.me’s channels. In line with Biotron’s business model, users will all be paid for contributing their data to the analytics products created by the partnership. The first-year goal of the cooperation is to gather data and provide it to relevant partners, such as research organisations.
Comment on this article below or via Twitter @IoTGN